相关实验视频

Updated: Jul 12, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

小分子向BCR-ABL在慢性髓性白血病治疗中的进展

Yuan Zhang¹, Xin Wu¹, Xueyan Sun¹

¹Department of Pharmacy, School of Pharmacy, Hengyang Medical School, Institute of Pharmacy and Pharmacology, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang, Hunan, 421001, China.

Mini reviews in medicinal chemistry

|October 19, 2023

概括

新的小分子药物,包括氨酸激酶抑制剂 (TKI) 和BCR-ABL蛋白降解剂,为慢性骨髓性白血病 (CML) 提供了新的治疗策略. 这些进展解决了早期治疗和耐药性的局限性,为改善CML管理铺平了道路.

科学领域:

血液学血液学血液学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

慢性骨髓性白血病 (CML) 是一种严重的血液性恶性瘤.
早期的CML治疗方法,如干扰素 (IFN-α) 和干细胞移植,存在局限性.
伊马替尼的出现,一个BCR-ABL激酶抑制剂,彻底改变了CML疗法,但面临着药物耐药性等挑战.

研究的目的:

审查目前用于CML治疗的小分子药物的现状.
突出新型治疗剂,包括氨酸激酶抑制剂 (TKI) 和BCR-ABL蛋白质降解剂.
讨论这些新兴的CML疗法的药理活性和潜力.

主要方法:

关于CML药物开发近期进展的文献综述.
针对BCR-ABL通路的小分子药物的分析.
候选药物的药理概要和治疗机制.候选药物的药理概要.

主要成果:

确定各种TKI和BCR-ABL蛋白降解剂作为有前途的CML治疗方法.
证明了超越传统酶抑制的新型作用机制.
克服耐药性突变的证据,例如T315I.

结论:

小分子药物代表了CML研究的一个动态领域.
新兴的TKI和蛋白质降解剂为CML患者提供了新的希望.
这些药物为未来的CML治疗策略提供了关键的见解.

关键词:

这是一种BCR-ABL蛋白质.在CML中,CML是CML.这是T315I突变.分子对接. 分子对接.针对蛋白质溶解的仿制化学物质.铁氨基激酶抑制剂铁氨基激酶抑制剂

更多相关视频

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...